https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-03-18 / Ann. Hematol. 2010 Aug;89(8):795-801
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-03-18 / Ann. Hematol. 2010 Aug;89(8):795-8012010-03-18 00:00:002019-02-15 08:40:19Alpha-type 1-polarized dendritic cells loaded with apoptotic allogeneic myeloma cell line induce strong CTL responses against autologous myeloma cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-03-17 / Cochrane Database Syst Rev 2010 Mar;(3):CD006377
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-03-17 / Cochrane Database Syst Rev 2010 Mar;(3):CD0063772010-03-17 00:00:002019-02-15 08:35:42Combined use of hyperthermia and radiation therapy for treating locally advanced cervix carcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-03-12 / Lung Cancer 2010 Nov;70(2):188-94
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-03-12 / Lung Cancer 2010 Nov;70(2):188-942010-03-12 00:00:002019-02-15 08:45:35Phase I study of autologous dendritic cell tumor vaccine in patients with non-small cell lung cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-03-11 / Curr. Opin. Immunol. 2010 Apr;22(2):258-63
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-03-11 / Curr. Opin. Immunol. 2010 Apr;22(2):258-632010-03-11 00:00:002019-02-15 08:40:24Building on dendritic cell subsets to improve cancer vaccines
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-03-10 / J. Cancer Res. Clin. Oncol. 2010 Nov;136(11):1745-54
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-03-10 / J. Cancer Res. Clin. Oncol. 2010 Nov;136(11):1745-542010-03-10 00:00:002019-02-15 09:11:45Increased prevalence of regulatory T cells in the tumor microenvironment and its correlation with TNM stage of hepatocellular carcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-03-05 / Cancer Immunol. Immunother. 2010 Oct;59(10):1573-82
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-03-05 / Cancer Immunol. Immunother. 2010 Oct;59(10):1573-822010-03-05 00:00:002019-02-15 08:40:24Toll-like receptor expression and function in human dendritic cell subsets: implications for dendritic cell-based anti-cancer immunotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-03-01 / Expert Opin Biol Ther 2010 Mar;10(3):369-79
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-03-01 / Expert Opin Biol Ther 2010 Mar;10(3):369-792010-03-01 00:00:002019-02-15 08:44:06The evolving role of dendritic cells in cancer therapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-03-01 / Immunol. Res. 2010 Mar;46(1-3):177-88
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-03-01 / Immunol. Res. 2010 Mar;46(1-3):177-882010-03-01 00:00:002019-02-15 09:17:28Fine-tuning immune surveillance by fever-range thermal stress
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-03-01 / Immunol. Res. 2010 Mar;46(1-3):137-54
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-03-01 / Immunol. Res. 2010 Mar;46(1-3):137-542010-03-01 00:00:002019-02-15 09:17:29Diverse immune mechanisms may contribute to the survival benefit seen in cancer patients receiving hyperthermia
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-03-01 / Immunotherapy 2010 Mar;2(2):185-99
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-03-01 / Immunotherapy 2010 Mar;2(2):185-992010-03-01 00:00:002019-02-15 09:21:47New perspectives in cancer virotherapy: bringing the immune system into play
